Pure Biologics S.A. (WSE:PUR)

Pure Biologics Income Statement

Financials in millions PLN. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	0.1	0.66	0.25	0.57
Revenue Growth (YoY)	-	-85.65%	160.63%	-55.59%	-67.79%
Cost of Revenue	0.05	2.67	6.07	4.28	4.51
Gross Profit	-0.05	-2.57	-5.41	-4.03	-3.94
Selling, General & Admin	14.92	38.01	28.71	20.69	20.46
Other Operating Expenses	-2.89	-16.25	-11.93	-17.15	-15.95
Operating Expenses	12.34	27.54	19.28	6.46	7.62
Operating Income	-12.38	-30.12	-24.68	-10.49	-11.56
Interest Expense	-1.33	-3.83	-0.33	-0.23	-0.35
Interest & Investment Income	-	0.28	0.2	0.09	0.03
Currency Exchange Gain (Loss)	-	-0.41	-0.02	-0.06	0.12
Other Non Operating Income (Expenses)	7.47	0	-	-	-
EBT Excluding Unusual Items	-6.25	-34.08	-24.83	-10.69	-11.76
Gain (Loss) on Sale of Investments	-	-0.02	-0.82	-1.09	-
Gain (Loss) on Sale of Assets	-	0.01	0.05	0.01	-
Other Unusual Items	-	-1.62	-	-	-
Pretax Income	-6.25	-35.69	-25.6	-11.77	-11.76
Net Income	-6.25	-35.69	-25.6	-11.77	-11.76
Net Income to Common	-6.25	-35.69	-25.6	-11.77	-11.76
Shares Outstanding (Basic)	-	3	2	2	2
Shares Outstanding (Diluted)	-	3	2	2	2
Shares Change (YoY)	-	41.50%	1.48%	34.29%	8.48%
EPS (Basic)	-	-11.19	-11.36	-5.30	-7.11
EPS (Diluted)	-	-11.19	-11.36	-5.30	-7.11
Free Cash Flow	-10.83	-23.44	-23.15	-24.71	-1.91
Free Cash Flow Per Share	-	-7.35	-10.27	-11.12	-1.16
Operating Margin	-	-31702.10%	-3728.40%	-4129.13%	-2020.10%
Profit Margin	-	-37572.63%	-3867.52%	-4631.89%	-2055.24%
Free Cash Flow Margin	-	-24671.58%	-3496.22%	-9727.56%	-334.62%
EBITDA	-12.08	-24.37	-22.46	-7.84	-8.66
D&A For EBITDA	0.31	5.75	2.23	2.65	2.9
EBIT	-12.38	-30.12	-24.68	-10.49	-11.56

Updated Nov 15, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.